GE HealthCare Technologies (NASDAQ:GEHC) Price Target Raised to $91.00

GE HealthCare Technologies (NASDAQ:GEHC) had its price target upped by equities research analysts at BTIG Research from $87.00 to $91.00 in a research report issued on Wednesday,Benzinga reports. The brokerage currently has a “buy” rating on the stock. BTIG Research’s target price indicates a potential upside of 9.79% from the stock’s current price.

GEHC has been the subject of a number of other research reports. Stifel Nicolaus lifted their price target on GE HealthCare Technologies from $90.00 to $95.00 and gave the company a “buy” rating in a research report on Wednesday, January 7th. Weiss Ratings restated a “hold (c+)” rating on shares of GE HealthCare Technologies in a research report on Monday, December 29th. The Goldman Sachs Group reaffirmed a “buy” rating and set a $98.00 target price on shares of GE HealthCare Technologies in a report on Friday, January 9th. Wells Fargo & Company reduced their price objective on GE HealthCare Technologies from $89.00 to $87.00 and set an “overweight” rating on the stock in a research note on Thursday, October 30th. Finally, Piper Sandler increased their target price on GE HealthCare Technologies from $91.00 to $94.00 and gave the company an “overweight” rating in a report on Friday. Seven analysts have rated the stock with a Buy rating, six have assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Hold” and a consensus target price of $90.67.

GE HealthCare Technologies Stock Performance

Shares of NASDAQ:GEHC traded up $4.10 during mid-day trading on Wednesday, reaching $82.88. The company had a trading volume of 2,573,897 shares, compared to its average volume of 3,471,408. The company’s 50-day moving average price is $82.64 and its 200-day moving average price is $77.43. GE HealthCare Technologies has a one year low of $57.65 and a one year high of $94.80. The firm has a market cap of $37.76 billion, a price-to-earnings ratio of 17.10, a PEG ratio of 2.42 and a beta of 1.08. The company has a current ratio of 1.18, a quick ratio of 0.95 and a debt-to-equity ratio of 0.83.

GE HealthCare Technologies (NASDAQ:GEHC) last issued its earnings results on Wednesday, February 4th. The company reported $1.44 earnings per share for the quarter, topping analysts’ consensus estimates of $1.43 by $0.01. GE HealthCare Technologies had a net margin of 10.94% and a return on equity of 22.52%. The firm had revenue of $5.70 billion during the quarter, compared to analyst estimates of $5.60 billion. During the same quarter last year, the business earned $1.45 earnings per share. The company’s quarterly revenue was up 7.1% on a year-over-year basis. GE HealthCare Technologies has set its FY 2026 guidance at 4.950-5.150 EPS. As a group, equities research analysts anticipate that GE HealthCare Technologies will post 4.68 EPS for the current fiscal year.

Institutional Trading of GE HealthCare Technologies

Several institutional investors and hedge funds have recently bought and sold shares of the stock. Laurel Wealth Advisors LLC bought a new position in shares of GE HealthCare Technologies in the 4th quarter worth approximately $26,000. Optima Capital LLC purchased a new stake in GE HealthCare Technologies in the fourth quarter worth about $27,000. Montag A & Associates Inc. lifted its holdings in shares of GE HealthCare Technologies by 105.4% during the fourth quarter. Montag A & Associates Inc. now owns 341 shares of the company’s stock valued at $28,000 after purchasing an additional 175 shares during the last quarter. Godsey & Gibb Inc. purchased a new position in GE HealthCare Technologies in the 3rd quarter worth approximately $26,000. Finally, E Fund Management Hong Kong Co. Ltd. lifted its position in GE HealthCare Technologies by 130.7% in the 3rd quarter. E Fund Management Hong Kong Co. Ltd. now owns 346 shares of the company’s stock valued at $26,000 after acquiring an additional 196 shares in the last quarter. 82.06% of the stock is currently owned by hedge funds and other institutional investors.

GE HealthCare Technologies News Summary

Here are the key news stories impacting GE HealthCare Technologies this week:

• Positive Sentiment: Q4 results narrowly beat expectations — EPS $1.44 vs. $1.43 consensus and revenue $5.70B vs. $5.60B, showing 7.1% year-over-year revenue growth; this validates near-term execution. GE HealthCare Technologies (GEHC) Q4 Earnings and Revenues Beat Estimates
• Positive Sentiment: Company forecasted 2026 profit above Wall Street estimates, citing strong demand for diagnostic and imaging devices — this raised the forward outlook and supports higher valuation expectations. GE HealthCare forecasts 2026 profit above estimates on strong demand for medical devices
• Positive Sentiment: Regulatory and product momentum: FDA clearance and CE mark for the Allia Moveo mobile C-arm (AI guidance, compact design) enable commercialization and early global installs — a tangible growth driver for imaging sales. GEHC Wins FDA Clearance & CE Mark for Allia Moveo, Marks Global Debut
• Neutral Sentiment: Company-released full Q4 and FY2025 results and commentary reiterate strategic focus on precision care, growth acceleration and business optimization — informative for modeling but largely consistent with the beats/guidance. GE HealthCare reports fourth quarter and full year 2025 financial results
• Neutral Sentiment: Analyst commentary and features frame GEHC as a long-term value/growth opportunity but note that near-term decisions depend on margin trends and capital allocation — useful context for longer-horizon investors. Why GE HealthCare Technologies (GEHC) is a Top Value Stock for the Long-Term
• Negative Sentiment: Profitability caveat: the WSJ notes Q4 profit fell despite higher revenue, and management described a “dynamic macroeconomic environment” — a reminder margins and cost pressures could limit upside if growth slows or costs rise. GE HealthCare Technologies Posts Lower Profit, Despite Higher Revenue
• Negative Sentiment: Analyst preview flagged risks from tariffs and ongoing investments that could keep margins under pressure even as revenue grows — watch margin guidance and gross-margin trends in upcoming quarters. GE HealthCare Stock Before Q4 Earnings: To Buy or Not to Buy?

About GE HealthCare Technologies

GE HealthCare Technologies (NASDAQ: GEHC) is a global medical technology and diagnostics company that develops, manufactures and markets a broad range of products and services for healthcare providers. Its portfolio centers on diagnostic imaging systems, including MRI, CT, PET and X-ray modalities, as well as ultrasound equipment. The company also supplies patient monitoring and anesthesia delivery systems, interventional and surgical imaging solutions, and molecular imaging technologies used in both clinical care and research settings.

In addition to hardware, GE HealthCare offers software, analytics and lifecycle services aimed at improving clinical workflows and equipment uptime.